on November 9, 2006
Published online before print November 9, 2006, doi: 10.1161/01.ATV.0000251995.73307.2d
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Submitted on July 2, 2006
Accepted on September 1, 2006
The Roles of Proteinase-Activated Receptors in the Vascular Physiology and Pathophysiology
Katsuya Hirano *
From the Division of Molecular Cardiology, Research Institute of Angiocardiology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
* To whom correspondence should be addressed. E-mail: khirano{at}molcar.med.kyushu-u.ac.jp.
Abstract--Proteinase-activated receptors (PARs) belong to a family of G protein-coupled receptors, thus mediating the cellular effects of proteinase. In the vascular system, thrombin and other proteinases in the coagulation-fibrinolysis system are considered to be the physiologically relevant agonists, whereas PARs are among the most important mechanisms mediating the interaction between the coagulation-fibrinolysis system and the vascular wall. Under physiological conditions, PARs are mainly expressed in endothelial cells, and participate in the regulation of vascular tone, mostly by inducing endothelium-dependent relaxation. PARs in endothelial cells are also suggested to contribute to a proinflammatory phenotypic conversion and an increase in the permeability of vascular lesions. In smooth muscle cells, PARs mediate contraction, migration, proliferation, hypertrophy, and production of the extracellular matrix, thereby contributing to the development of vascular lesions and the pathophysiology of such vascular diseases as atherosclerosis. However, the expression of PARs in the smooth muscle of normal arteries is limited. The upregulation of PARs in the smooth muscle is thus considered to be a key step for PARs to participate in the pathogenesis of vascular lesions. Elucidating the molecular mechanism regulating the PARs expression is therefore important to develop new strategies for the prevention and treatment of vascular diseases.
Key words: thrombin • receptors • vascular biology • endothelium • smooth muscle
This article has been cited by other articles:
 |
|
 |
|
  J. Orbe, J. A. Rodriguez, O. Calvayrac, R. Rodriguez-Calvo, C. Rodriguez, C. Roncal, S. Martinez de Lizarrondo, J. Barrenetxe, J. C. Reverter, J. Martinez-Gonzalez, et al. Matrix Metalloproteinase-10 Is Upregulated by Thrombin in Endothelial Cells and Increased in Patients With Enhanced Thrombin Generation Arterioscler Thromb Vasc Biol, December 1, 2009; 29(12): 2109 - 2116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. P. Kastl, W. S. Speidl, K. M. Katsaros, C. Kaun, G. Rega, A. Assadian, G. W. Hagmueller, M. Hoeth, R. de Martin, Y. Ma, et al. Thrombin induces the expression of oncostatin M via AP-1 activation in human macrophages: a link between coagulation and inflammation Blood, September 24, 2009; 114(13): 2812 - 2818. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Seehaus, K. Shahzad, M. Kashif, I. A. Vinnikov, M. Schiller, H. Wang, T. Madhusudhan, V. Eckstein, A. Bierhaus, F. Bea, et al. Hypercoagulability Inhibits Monocyte Transendothelial Migration Through Protease-Activated Receptor-1-, Phospholipase-C{beta}-, Phosphoinositide 3-Kinase-, and Nitric Oxide-Dependent Signaling in Monocytes and Promotes Plaque Stability Circulation, September 1, 2009; 120(9): 774 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. W. Stevens and S. R. Lentz Countervailing Effects on Atherogenesis and Plaque Stability: A Paradoxical Benefit of Hypercoagulability? Circulation, September 1, 2009; 120(9): 722 - 724. [Full Text] [PDF]
|
|
|
|
 |
|
 J. I. Borissoff, H. M.H. Spronk, S. Heeneman, and H. ten Cate Is thrombin a key player in the 'coagulation-atherogenesis' maze? Cardiovasc Res, June 1, 2009; 82(3): 392 - 403. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Zania, D. Gourni, A. C. Aplin, R. F. Nicosia, C. S. Flordellis, M. E. Maragoudakis, and N. E. Tsopanoglou Parstatin, the Cleaved Peptide on Proteinase-Activated Receptor 1 Activation, Is a Potent Inhibitor of Angiogenesis J. Pharmacol. Exp. Ther., February 1, 2009; 328(2): 378 - 389. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. L. Watts and E. D. Motley Role of Protease-Activated Receptor-1 in Endothelial Nitric Oxide Synthase-Thr495 Phosphorylation Experimental Biology and Medicine, February 1, 2009; 234(2): 132 - 139. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Perez Sastre, S. Grossmann, H. P. Reusch, and M. Schaefer Requirement of an Intermediate Gene Expression for Biphasic ERK1/2 Activation in Thrombin-stimulated Vascular Smooth Muscle Cells J. Biol. Chem., September 19, 2008; 283(38): 25871 - 25878. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Weiler and W. Ruf PAR4 antagonists in inflammation Blood, November 1, 2007; 110(9): 3091 - 3092. [Full Text] [PDF]
|
|
|
|
|
|
K. Hirano, N. Nomoto, M. Hirano, F. Momota, A. Hanada, and H. Kanaide Distinct Ca2+ Requirement for NO Production between Proteinase-Activated Receptor 1 and 4 (PAR1 and PAR4) in Vascular Endothelial Cells J. Pharmacol. Exp. Ther., August 1, 2007; 322(2): 668 - 677. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Fujiyoshi, K. Hirano, M. Hirano, J. Nishimura, S. Takahashi, and H. Kanaide Plasmin Induces Endothelium-Dependent Nitric Oxide-Mediated Relaxation in the Porcine Coronary Artery Arterioscler Thromb Vasc Biol, April 1, 2007; 27(4): 949 - 954. [Abstract] [Full Text] [PDF]
|
|